Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Pheno Therapeutics has been granted two key patents protecting its GPR17 antagonist pipeline for neurological diseases. The patents cover PTD802 — a remyelination-promoting therapy for multiple sclerosis already cleared for clinical trials in the UK and US — and PTD939, a second candidate targeting ALS. A first-in-human trial for PTD802 is set to kick off in Q4 2026.
Pheno Therapeutics has secured two new patents that strengthen its intellectual property position around its GPR17 (G protein-coupled receptor 17) antagonist pipeline, aimed at treating neurological and neurodegenerative diseases. The first patent (GB2642355) covers a specific crystalline form of PTD802, the company's lead candidate designed to promote remyelination in multiple sclerosis (MS). The second (GB2700773) provides composition-of-matter protection — the gold standard of drug IP — for PTD939, a second program initially targeting amyotrophic lateral sclerosis (ALS).
PTD802 has already cleared regulatory hurdles on both sides of the Atlantic, receiving Clinical Trial Authorization from the UK's MHRA and Investigational New Drug clearance from the US FDA — making it the first GPR17 program to achieve IND clearance. A first-in-human study evaluating safety and tolerability in healthy volunteers is slated to begin in Q4 2026.
Key Takeaways:
Why it matters: GPR17 is an emerging therapeutic target in neurodegeneration, and these patents give Pheno a layered IP shield as it advances toward clinical trials — a critical step in validating a novel mechanism that could eventually offer new treatment options for MS and ALS patients.